Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
A Retrospective Study of Progression-Free and Overall Survival in Pediatric Medulloblastoma Based on Molecular Subgroup Classification: A Single-Institution Experience
First author：Wang, Ying Li, Chunde
Corresponding author：Li, Chunde
essential_information
- Person in charge：Wang, Ying Li, Chunde
- Data Sources： OTHERS
- Number of papers：OTHERS20190516
- Published time：2017-05-12
2017-05-12
Published articles
Journal：Front Neurol
Publication type: Original Research
IF(IF): 4.003
PMID: 28553259 Link To Pubmed Full text Download
Background And Purpose
Method
From January 2011 to January 2013, 84 consecutive MB patients aged underwent tumor removal at Beijing Tiantan Hospital. A total of 55 patients who ranged in age from 4 to 18 years underwent detailed follow-up. Molecular subgrouping was performed using RT-PCR.
Conclusion
In our study, the non-metastasized Group 4 patients had an excellent prognosis. The SHH subgroup and Group 3 patients had worst prognoses. LC/A histology had a dismal prognosis in our cohorts, which warrants intensive treatment.
Main results
The 2-year progression-free survival (PFS) and overall survival (OS) rates for the entire cohort were 76.2 ± 5.8 and 81.8 ± 5.2%, respectively. Univariate analysis revealed that the Group 4 patients had a better survival (2-year OS, 90.6 ± 5.2%) than the SHH subgroup (P = 0.002) and Group 3 patients (P = 0.008). Only two of the 23 non-metastasized Group 4 patients relapsed, and chemotherapy did significantly affect these patients (PFS, P = 0.685). One out of five WNT patients had tumor relapse and died at last. Large cell/anaplastic (LC/A) histology and chemotherapy were independent risk factors in multivariate analysis.